|
|
Asymptomatic pt w/ PSA 50 ng/mL and 3 rib mets (PS = 0)?Asymptomatic pt w/ PSA 50 ng/mL and 3 rib mets (PS = 0)?A 62-year-old asymptomatic man with a good performance status (PS = 0) presents de novo with a PSA of 50 ng/mL and 3 isolated rib metastases. What systemic treatment approach would you generally recommend, and what bone-targeted treatment, if any, would you recommend at this time? How would you care for the same patient if he were 80 years old? Crawford ED et al. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology 2014;83(5):1122-8. Abstract Gravis G et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial. Lancet Oncol 2013;14(2):149-58. Abstract Hussein A et al. Prevalence of first and subsequent skeletal-related events (SREs) in US elderly patients with metastatic prostate cancer (mPC). Proc ASCO 2014;Abstract e16006. Shore ND. Experience with degarelix in the treatment of prostate cancer. Ther Adv Urol 2013;5(1):11-24. Abstract Smith MR et al. Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance). Genitourinary Cancers Symposium 2013;Abstract 27. |